1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awduron:	Martin Reck, Alexander I. Spira, Benjamin Besse, Jennifer Moriatis Wolf, Ferdinandos Skoulidis, Hossein Borghaei, Kōichi Goto, K. Park, Frank Griesinger, Enriqueta Felip, Michael Boyer, Carlos H. Barrios, Glenwood Goss, Hui Yang, Cynthia Obiozor, Suresh S. Ramalingam
Fformat:	Artigo
Iaith:	Saesneg
Cyhoeddwyd:	2020
Mynediad Ar-lein:	https://doi.org/10.1016/j.annonc.2020.08.1730 http://www.annalsofoncology.org/article/S0923753420417260/pdf
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd